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Summary
Background: Time from hospital arrival to reperfusion in ST-segment elevation myocardial
infarction (STEMI) has been predictive of in-hospital mortality. The purpose of this study was
to evaluate the relationship between symptom-onset-to-balloon time and long-term mortality
in patients with STEMI in the drug-eluting stent (DES) era.
Methods: A series of 393 patients with STEMI treated with DES from 2005 to 2007 was stratiﬁed
according to risk proﬁle and preprocedural Thrombolysis In Myocardial Infarction (TIMI) ﬂow
grade, and clinical, angiographic, and follow-up data were collected.
Results: A total of 98 (24.9%) low-risk patients and 295 (75.1%) non-low-risk patients were identi-
ate was 3.1% for low-risk patients and 10.2% for non-low-risk patientsﬁed. Three-year mortality r
(p = 0.034), respectively; however it did not differ according to symptom-onset-to-balloon time
in either low-risk (p = 0.333) or non-low-risk patients (p = 0.881). Similarly, symptom-onset-to-
balloon time and mortality were not related to preprocedural TIMI ﬂow (p = 0.474 for TIMI 0—1;
p = 0.428 for TIMI 2—3). In multivariate analysis, ﬁnal TIMI ﬂow 0—2, systolic blood pressure
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<100mmHg at admission, age ≥70 years, anterior infarction, C-reactive protein level, and peak
creatine kinase myocardial band isoenzyme level were identiﬁed as independent predictors of
3-year mortality while symptom-onset-to-balloon time and preprocedural TIMI ﬂow were not.
Conclusions: In STEMI patients treated with DES, symptom-onset-to-balloon time does not affect
long-term outcomes even in individuals at non-low risk and with poor preprocedural TIMI ﬂow
grade.
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categories of treatment times were assessed by the
Kaplan—Meier method using the log-rank test. Predictors
of late cardiac mortality were performed using Cox pro-© 2011 Japanese College of C
ntroduction
rompt restoration of coronary artery blood ﬂow using
rimary percutaneous coronary intervention (PCI) or ﬁb-
inolytic therapy improves outcomes in patients with
T-segment elevation myocardial infarction (STEMI). If
erformed in a timely fashion, primary PCI is pre-
erred based on randomized trials documenting bet-
er outcomes compared to ﬁbrinolytic therapy. How-
ver, published data on symptom-onset-to-balloon time
nd mortality have been inconsistent [1—13]. More-
ver, most reports assessing the inﬂuence of symptom-
nset-to-balloon time on mortality in patients with
TEMI were limited to studies after bare-metal stent
mplantation, with most studies having follow-up of
1 year. The present study assesses the effect of
ymptom-onset-to-balloon time on 3-year mortality in
atients with STEMI treated with drug-eluting stents
DES).
ethods
tudy population
rom 2005 to 2007, a total of 404 patients with STEMI
ere treated with DES. Of these, 11 (2.7%) patients were
ost to follow up and were excluded from the anal-
sis. An institutional review board approved the study
nd all participants provided written informed consent.
ll patients presenting within 6 h from symptom onset
r between 6 and 24 h if they had continuing chest
ain and/or ST-segment elevation on electrocardiogram
ere included without any restriction based on age,
ender, or clinical status on presentation. The exclu-
ion criteria for this study were: (1) previous ﬁbrinolytic
reatment, and (2) inability to provide informed con-
ent. Angiographic criteria for exclusion were: (1) diameter
tenosis of the infarct-related artery <70% on visual esti-
ation, and (2) inability to identify the infarct-related
rtery.
reatment protocol
remedication consisted of aspirin (300mg daily) and clopi-
ogrel (600mg loading) before PCI. A bolus of heparin
00U/kg was administered after sheath insertion with a
epeat bolus to keep an activated clotting time ≥250 s. After
he intervention, the patients received aspirin (100—200mg
aily) indeﬁnitely and clopidogrel (75mg daily) for at least
2 months. The use of glycoprotein IIb/IIIa inhibitors was at
he discretion of the physician.
p
t
tology. Published by Elsevier Ltd. All rights reserved.
ata analysis
e divided the patients into 4 groups (≤2 h, between 2 and
h, between 4 and 6 h, and >6 h) according to the time
rom symptom onset to ﬁrst balloon inﬂation (symptom-
nset-to-balloon time). Patients were stratiﬁed according
o the main risk proﬁle criteria proposed by Thrombolysis
n Myocardial Infarction (TIMI) investigators [14]. The pres-
nce of one or more TIMI criteria [age >70 years, anterior
yocardial infarction, heart rate ≥100 beats/min at admis-
ion, previous myocardial infarction, systolic blood pressure
BP) <100mmHg, or cardiogenic shock] was used to stratify
atients into ‘‘low-risk’’ and ‘‘non-low-risk’’ categories.
ngiographic analysis
ll angiograms were reviewed by two experienced physi-
ians. Coronary ﬂow in the infarct-related artery was graded
ccording to the TIMI study group classiﬁcation [15]. Col-
ateral ﬂow before PCI was graded using the classiﬁcation
eveloped by Rentrop et al. [16]. Quantitative coronary
ngiographic analysis was performed by on line analysis sys-
em (CAAS QCA V2.0.1, Pie Medical Imaging B.V., Maastricht,
he Netherlands). Coronary occlusion was assigned a value
f 0mm for minimal lumen diameter and 100% for percent
iameter stenosis. Procedural success was deﬁned as post-
rocedural TIMI 3 ﬂow and a residual stenosis <30%.
linical and angiographic follow-up
linical follow-up was done by hospital and ofﬁce chart
eview and direct telephone interview with the patient. For
atients who died during follow-up, hospital records were
eviewed. Mean follow-up period was 18± 11 months. Rou-
ine angiographic follow-up was recommended at 8 months
fter index procedure or earlier if clinically indicated by
ymptoms or documentation of myocardial ischemia.
tatistical analysis
or comparison of categorical variables, chi-square test
as used. Continuous variables are presented as mean
alues (±standard deviation), and statistical comparisons
ere performed using two-tailed Student’s t-test or anal-
sis of variance. Differences in late cardiac survival acrossortional hazards regression models. Variables entered into
he models were age, gender, hypertension, anterior infarc-
ion, previous infarction, left ventricular ejection fraction
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PSymptom-onset-to-balloon time in patients with acute myoc
(LVEF), multivessel disease, peak creatine kinase myocardial
band isoenzyme (CK-MB) level, use of glycoprotein IIb/IIIa
inhibitor, use of intra-aortic balloon counterpulsation (IABP),
and preprocedural TIMI ﬂow grade. All statistical analyses
were performed using SPSS software (version 15.0, SPSS Inc,
Chicago, IL, USA). A p-value <0.05 was considered to indicate
statistical signiﬁcance.
Results
Baseline characteristics
The mean symptom-onset-to-balloon time was 5.5± 4.5 h.
Demographic, angiographic, and procedural characteristics
according to symptom-onset-to-balloon time are shown in
Table 1. Patients with longer symptom-onset-to-balloon
time were more often women, and had a higher fre-
quency of diabetes. Anterior infarction, previous infarction,
and pre/post-procedural TIMI ﬂow grade were not differ-
ent according to symptom-onset-to-balloon time. LVEF was
lower in patients with longer symptom-onset-to-balloon
time. Of the 393 patients, 98 (24.9%) were low-risk, and 295
(75.1%) were non-low-risk. Baseline characteristics of the
2 groups are listed in Table 2. Non-low-risk patients had a
mean age of 64± 12 years; 67.1% had an anterior infarction,
and 17.1% had a systolic BP <100mmHg at admission.
In-hospital and long-term clinical outcomes by
symptom-onset-to-balloon time
In-hospital mortality did not differ signiﬁcantly accord-
ing to symptom-onset-to-balloon time (Table 3). Prolonged
symptom-onset-to-balloon time (0—2h vs. 2—4 h vs. 4—6 h.
vs. ≥6 h) was associated with neither higher long-term mor-
tality (7.1% vs. 9.1% vs. 10.3% vs. 6.6% at 3 years, p = 0.761)
nor major adverse cardiac events (14.3% vs. 16.7% vs. 13.4%
vs. 10.7% at 3 years, p = 0.582). As shown in Table 4, ﬁnal
TMI ﬂow 0—2, systolic BP <100mmHg at admission, age
≥70 years, anterior infarction, C-reactive protein level, and
peak CK-MB level were signiﬁcant independent predictors
of long-term cardiac mortality whereas preprocedural TIMI
ﬂow grade and symptom-onset-to-balloon time were not.
Long-term clinical outcomes by
symptom-onset-to-balloon time in patient
subgroups
The relation between symptom-onset-to-balloon time and
mortality was investigated in low-risk and non-low-risk
patients. A total of 98 (24.9%) low-risk patients and 295
(75.1%) non-low risk patients were identiﬁed, and the
effects of symptom-onset-to-balloon times on long-term
cardiac mortality in these subgroups of patients are shown
in Fig. 1A. Three-year mortality was signiﬁcantly lower in
low-risk patients (3.1% vs. 10.2%, respectively; p = 0.034).
However, as shown in Fig. 2A, 3-year mortality according
to symptom-onset-to-balloon time was similar in low-risk
(p = 0.333) and non-low-risk patients (p = 0.881). To exam-
ine the inﬂuence of preprocedural TIMI ﬂow grade on the
prognostic role of symptom-onset-to-balloon time, patients
n
t
s
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ere divided according to preprocedural TIMI 0—1 ﬂow
230 patients (58.5%)] and TIMI 2—3 ﬂow [163 patients
41.5%)]. As shown in Fig. 1B, 3-year mortality was sim-
lar among the different TIMI ﬂow groups (8.3% vs. 8.6%,
espectively; p = 0.908), while Fig. 2B shows that symptom-
nset-to-balloon time and mortality are not related to
reprocedural TIMI ﬂow grade (p = 0.474 for TIMI 0—1,
= 0.428 for TIMI 2—3). Kaplan—Meier survival curves show
hat 3-year death-free survival rates did not differ according
o symptom-onset-to-balloon time and preprocedural TIMI
ow grade (Fig. 3).
iscussion
he major ﬁndings of this study are that among patients with
TEMI treated with DES undergoing primary PCI, symptom-
nset-to-balloon-time does not affect long-term outcomes
ccording to baseline risk status and preprocedural TIMI ﬂow
rade. In this study, symptom-onset-to-balloon time and pre-
rocedural TIMI ﬂow grade were not independent predictors
f long-term cardiac mortality.
It has been suggested that very early reperfusion
mproves survival by enhancing myocardial salvage and that
ater reperfusion enhances survival through the effects of
pening infarct-related artery on left ventricular remodeling
nd electrical instability caused by infarcted myocardium
17]. Prompt and appropriate reperfusion of infarct-related
rtery is more important than the selection of stents [18] or
ntiplatelet regimens [19] to improve clinical outcomes in
TEMI patients. The beneﬁt of ﬁbrinolytic therapy is greatest
hen used within the ﬁrst few hours after symptom onset,
articularly within the ﬁrst 70min [20], and the beneﬁcial
ffect of time-to-ﬁbrinolysis on infarct size and LVEF was
imited to treatment given within 2 h after symptom onset
21]. However, a substantial proportion of STEMI patients
resent at a later time [22—25].
There have been conﬂicting data on whether symptom-
nset-to-balloon time predicts long-term clinical out-
omes in STEMI patients treated with primary PCI.
lthough some studies have shown a positive rela-
ionship between symptom-onset-to-balloon time and
ortality [4,6—8,10,11], especially in high-risk patients
6,7,10], other studies failed to demonstrate this rela-
ionship [1—3,5,9,12,13]. A signiﬁcant correlation between
ymptom-onset-to-balloon time and 1-year mortality was
lso reported by De Luca et al. [10]. There was a signif-
cant correlation between symptom-onset-to-balloon time
nd mortality at 1 year for STEMI patients with non-low risk
nd for those with preprocedural TIMI ﬂow grade 0 or 1. Data
n support for a lack of association comes from the Second
ational Registry of Myocardial Infarction (NRMI-2) including
7,080 patients from before the stent era who underwent
alloon angioplasty for treatment of STEMI [5]. They con-
luded that there was no correlation between the time from
ymptom onset to balloon inﬂation and in-hospital mortal-
ty. The stent PAMI trial of 1232 STEMI patients with primary
CI, which did not include patients in cardiogenic shock,
oted a similar lack of association between symptom-onset-
o-balloon time and mortality [26]. Results of the present
tudy correspond with those of earlier studies revealing lack
f association between symptom-onset-to-balloon time and
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Table 1 Baseline clinical, angiographic, and procedural characteristics.
Characteristics ≤2 h 2—4h 4—6h >6 h p-Value
Number of patients 42 132 97 122
Age (years) 59± 12 63± 12 63± 11 63± 12 0.242
Male, gender 39 (92.7%) 104 (78.8%) 74 (76.3%) 86 (70.5%) 0.027
Hypertension 17 (40.5%) 61 (46.2%) 34 (35.8%) 50 (41.3%) 0.475
Diabetes 6 (14.3%) 30 (22.7%) 19 (19.6%) 44 (36.1%) 0.006
Anterior infarction 24 (57.1%) 61 (46.2%) 49 (50.5%) 65 (53.3%) 0.555
Previous infarction 0 4 (3.1%) 3 (3.1%) 8 (6.6%) 0.215
Multivessel disease 26 (63.4%) 67 (50.8%) 55 (56.7%) 75 (61.5%) 0.286
Pre-TIMI 0—1 ﬂow 24 (57.1%) 76 (57.6%) 64 (66.0%) 66 (54.1%) 0.349
Post-TIMI 3 ﬂow 36 (85.7%) 116 (87.9%) 82 (84.5%) 114 (93.4%) 0.186
Basal CK-MB level 40.2± 96.4 17.7± 51.0 35.2± 82.8 52.8± 113.2a 0.016
Peak CK-MB level 180.6± 136.6 206.2± 153.9 227.3± 184.7 217.3± 184.7 0.780
LVEF, % 50.0± 10.4 50.3± 9.2 47.2± 8.6 48.4± 9.5a 0.016
Target vessel 0.720
LAD 27 (57.1%) 61 (46.2%) 49 (50.5%) 65 (53.3%)
LCX 4 (9.5%) 11 (8.3%) 13 (13.4%) 11 (9.0%)
RCA 13 (31.0%) 59 (44.7%) 33 (34.0%) 44 (36.1%)
Left main 1 (2.4%) 1 (0.8%) 2 (2.1%) 2 (1.6%)
Use of IABP 5 (11.9%) 17 (12.9%) 18 (18.6%) 17 (13.9%) 0.609
Use of GP IIb/IIIa inhibitor 4 (9.5%) 22 (16.7%) 14 (14.4%) 16 (13.2%) 0.682
Use of aspirin 41 (97.6%) 128 (97.0%) 95 (97.9%) 115 (94.3%) 0.854
Use of statin 35 (83.3%) 112 (84.8%) 80 (82.5%) 101 (82.8%) 0.652
Thrombectomy 7 (16.7%) 15 (11.4%) 14 (14.4%) 20 (16.4%) 0.668
Multivessel PCI 9 (22.0%) 37 (28.5%) 21 (21.6%) 31 (25.8%) 0.652
Data shown as number (%) or mean± SD. TIMI, thrombolysis in myocardial infarction; CK-MB, creatine-kinase myocardial band isoenzyme;
LVEF, left ventricular ejection fraction; LAD, left anterior descending artery; LCX, left circumﬂex artery; RCA, right coronary artery;
IABP, intra-aortic balloon counterpulsation; GP, glycoprotein; PCI, percutaneous coronary intervention.
a p-Value <0.05 vs. 2—4 h.
Table 2 Patient characteristics according to risk status.
Characteristics Low-risk Non-low-risk p-Value
Number of patients 98 295
Age (years) 58± 10 64± 12 <0.001
Male, gender 79 (80.6%) 224 (75.9%) 0.339
Hypertension 36 (36.7%) 126 (43.2%) 0.265
Diabetes 25 (25.5%) 74 (25.1%) 0.933
Anterior infarction 1 (1.0%) 198 (67.1%) <0.001
Hypercholesterolemia 27 (28.4%) 73 (26.2%) 0.668
Previous infarction 4 (4.1%) 14 (4.8%) 0.781
Systolic BP <100mmHg 1 (2.6%) 31 (17.1%) 0.022
Collateral ﬂow Rentrop grade >1 27 (27.6%) 61 (20.7%) 0.321
Multivessel disease 45 (45.9%) 178 (60.5%) 0.011
Basal CK-MB level 20.8± 54.8 40.1± 95.7 0.059
Peak CK-MB level 227.9± 421.6 206.7± 95.7 0.477
LVEF, % 55.2± 8.0 46.0± 8.9 <0.001
Type B2/C lesion 82 (83.7%) 231 (79.7%) 0.384
Use of IABP 8 (8.2%) 49 (16.6%) 0.040
Use of GP IIb/IIIa inhibitor 12 (12.2%) 44 (15.0%) 0.505
Thrombectomy 11 (11.2%) 45 (15.3%) 0.323
Multivessel PCI 26 (26.5%) 72 (24.8%) 0.737
Symptom-onset-to-balloon time (h) 6.2± 6.3 6.1± 5.3 0.857
Data shown as number (%) or mean± SD. BP, blood pressure; CK-MB, creatine-kinase myocardial band isoenzyme; LVEF, left ventricular
ejection fraction; IABP, intra-aortic balloon counterpulsation; GP, glycoprotein; PCI, percutaneous coronary intervention.
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Table 3 Clinical outcomes.
≤2 h 2—4h 4—6h >6 h p-Value
In-hospital event
Death 2 (4.8%) 9 (6.8%) 7 (7.2%) 5 (4.1%) 0.724
MI 1 (2.4%) 0 0 0 0.039
TVR 0 0 1 (1.0%) 0 0.383
Long-term event
Death 3 (7.1%) 12 (9.1%) 10 (10.3%) 8 (6.6%) 0.761
MI 1 (2.4%) 1 (0.8%) 1 (1.0%) 2 (1.6%) 0.834
TVR 3 (7.1%) 12 (9.1%) 2 (2.1%) 3 (2.5%) 0.040
MACE 6 (14.3%) 22 (16.7%) 13 (13.4%) 13 (10.7%) 0.582
Data shown as numbers (%). MI, myocardial infarction; TVR, target vessel revascularization; MACE, major adverse cardiac events.
Table 4 Predictors of cardiac death by Cox-proportional hazards model.
Variables Hazard ratio 95% Conﬁdence interval p-Value
Final TIMI ﬂow 0—2 5.87 1.90—18.16 0.002
Systolic BP <100mmHg 4.18 1.90—9.23 0.001
Age ≥70 years 4.07 1.50—11.10 0.006
Anterior infarction 3.76 1.21—11.66 0.022
C-reactive protein level 1.09 1.02—1.16 0.008
Peak CK-MB level 0.99 0.98—0.99 0.007
K-MB,
p
T
tTIMI, thrombolysis in myocardial infarction; BP, blood pressure; C
mortality. It has been assumed that the apparent lack of
relation between mortality and symptom-onset-to-balloon
time might be due to discordance between the time of
symptom onset and the time of coronary occlusion. Another
possible explanation is the selection of patients who do not
die before hospital arrival. Thus, this phenomenon could be
explained by a survivor cohort effect in which those who
w
b
n
t
Figure 1 Bar graph depicting 3-year mortality according to risk sta
(TIMI) ﬂow (B).creatine-kinase myocardial band isoenzyme.
resented to the hospital had survived the ﬁrst few hours.
he reasons for these disparate results on the importance of
ime from symptom onset are not well understood. Similarly,
e analyzed the prognostic impact of symptom-onset-to-
alloon time according to patient risk status, but we could
ot ﬁnd a signiﬁcant relationship between symptom-onset-
o-balloon time and long-term mortality. However, the
tus (A) and preprocedural Thrombolysis In Myocardial Infarction
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bigure 2 Bar graph depicting 3-year mortality according to
on-low-risk patients (A) and in preprocedural Thrombolysis In
bsolute numbers of patients were too small to achieve
tatistical signiﬁcance and deﬁnitive conclusions could be
btained from large-scale studies with sufﬁcient statistical
ower to detect differences in long-term mortality rates.
This lack of association between reperfusion time and
ortality with primary PCI is in contrast to the case with
hrombolytic therapy, for which mortality increases progres-
ively with increasing time to treatment [27]. One possible
xplanation for this disparity is that the proportion of cases
ith TIMI 3 ﬂow rate decrease with increasing time to treat-
ent in patients with thrombolytic therapy [28,29], whereas
t remains high regardless of reperfusion time in this study
nd other studies with primary PCI [1,26]. Also, death asso-
iated with myocardial rupture increases progressively with
ncreasing time to treatment with thrombolytic therapy
30], while it is uncommon with primary PCI [31]. In addition,
ulprit lesions in infarct-related arteries in STEMI already
t
i
m
T
igure 3 Kaplan—Meier survival curves for death in low-risk (A)
alloon time.ptom-onset-to-balloon time in all patients, low-risk patients,
ardial Infarction (TIMI) ﬂow 2—3 patients, 0—1 patients (B).
ave more plaque rupture, thrombus, and higher frequency
f plaque prolapse compared with lesions in non-STEMI [32].
This study is a retrospective non-randomized analysis.
onuniform distribution of patient risk proﬁle according to
ymptom-onset-to-balloon time and the small sample popu-
ation might explain why risk status and TIMI ﬂow grade did
ot inﬂuence mortality rates according to symptom-onset-
o-balloon time. The low mortality and reinfarction rates
n this trial limit the power of our analyses. Also, a sub-
tantial proportion (41.5%) of patients had TIMI 2 or 3 ﬂow
n baseline angiography; reperfusion occurred before bal-
oon angioplasty and the actual reperfusion time is unknown.
owever, our study indicates that symptom-onset-to-balloon
ime does not have a major impact on mortality, suggest-
ng that the survival beneﬁt of primary PCI in DES era
ay be related to factors other than myocardial salvage.
he high rates of TIMI 3 ﬂow in our study, regardless of
and non-low-risk patients (B) according to symptom-onset-to-
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symptom-onset-to-balloon time, suggest that opening the
infarct-related artery, rather than reperfusion time, might
be the primary determinant of survival after primary PCI for
STEMI.
In conclusion, our study demonstrated that high-risk fea-
tures are associated with increased long-term mortality in
STEMI patients undergoing primary PCI using DES implan-
tation. The results obtained here suggest that long-term
mortality rate does not increase signiﬁcantly in non-low-risk
and low-risk subjects with increasing symptom-onset-to-
balloon time. Additionally, we found that preprocedural TIMI
ﬂow grade is not related to long-term survival according to
symptom-onset-to-balloon time. Furthermore, ﬁnal TMI ﬂow
0—2, systolic BP <100mmHg at admission, age ≥70 years,
anterior infarction, C-reactive protein level, and peak CK-
MB level were identiﬁed as independent predictors of 3-year
mortality.
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